步长制药(603858.SH)：布洛芬缓释胶囊获得药品注册证书

Core Viewpoint - The company, Bichang Pharmaceutical (603858.SH), has received approval from the National Medical Products Administration for its Ibuprofen Sustained-Release Capsules, indicating a significant advancement in its product offerings [1]. Group 1: Product Approval - Bichang Pharmaceutical's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Ibuprofen Sustained-Release Capsules [1]. - The approved indication for the Ibuprofen Sustained-Release Capsules includes relief for mild to moderate pain such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea [1]. - Additionally, the capsules are indicated for fever caused by common colds or influenza [1].